⌕
Kestra Medical Technologies · KMTS · Nasdaq
Tenet 39 · Weak
Compare
$28.27+1.07%At closeTenet 39 · Weak
$28.27+0.30 (+1.07%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kestra Medical Technologies (KMTS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

14 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~84.9%/yr (FY24→FY26), net margin −138.4%.
The four lines that matter · FY24–FY26
Revenue ($M)▲59.0%
95.1
FY24→FY26CAGR +84.9%/yr
Net income ($M)▼15.6%
−131.6
FY24→FY26CAGR —
Free cash flow ($M)▼16.0%
−116.6
FY24→FY26CAGR —
Diluted EPS▲52.6%
−2.43
FY24→FY26CAGR —
What the income statement says · FY24–FY26
Where every revenue dollar goes · FY26 ($M)95.1Revenue−46.3COGS48.9Gross profit−19.5R&D−164.1SG&A−134.7Op income3.1Tax & other−131.6Net income

-138¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
604530150%sector median net margin ~3%FY24FY26

Over this window: gross 1.3% → 51.4%. Net margin -138.4% is below the sector median.

The receipt · income statement · FY24–FY26 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY26FY25FY24YoYCAGR 24→26
Revenue & profitability
Revenue
71,415.095,126.059,815.027,814.0▲59.0%+84.9%
Cost of revenue
38,558.046,263.035,605.027,452.0▲29.9%+29.8%
Gross profit
32,857.048,863.024,210.0362.0▲101.8%+1061.8%
Research & development
18,447.019,484.015,652.015,490.0▲24.5%+12.2%
Selling, general & admin
129,567.0164,120.0114,936.069,935.0▲42.8%+53.2%
Total operating expenses
148,014.0183,604.0130,588.085,425.0▲40.6%+46.6%
Operating incomefeeds ROC rank
−115,157.0−134,741.0−106,378.0−85,063.0▼26.7%—
Other income, net
−16,766.03,423.0−7,301.0−9,033.0——
Pretax income
−131,923.0−131,318.0−113,679.0−94,096.0▼15.5%—
Income tax
152.0294.0135.024.0▲117.8%+250.0%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−132,075.0−131,612.0−113,814.0−94,120.0▼15.6%—
Per share
Diluted EPSbuyback-sensitive
−5.38−2.43−5.13−5.07▲52.6%—
Diluted shares (mn)
58.5754.1824.5819.89▲120.4%+65.1%
Margins
Gross margin25th pct in Healthcare
46.0%51.4%40.5%1.3%▲10.9pp+50.1pp
Operating margin
−161.3%−141.6%−177.8%−305.8%▲36.2pp+164.2pp
Net margin8th pct in Healthcare
−184.9%−138.4%−190.3%−338.4%▲51.9pp+200.0pp
† TTM = trailing four quarters through 2026-07-31.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-07-14 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Kestra Medical Technologies' revenue last fiscal year?

Kestra Medical Technologies reported revenue of $95.1M in fiscal 2026, up 59.0% from fiscal 2025.

What was Kestra Medical Technologies' net income?

Kestra Medical Technologies reported net income of −$131.6M in fiscal 2026, a net margin of −138.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.